Which genetics companies have filed or debuted publicly in the last 45 days?

Within this window, Ultima Genomics confidentially submitted for a US IPO on January 9, 2026, according to Bloomberg. GC Genome priced and listed on Kosdaq on January 8, 2026, as reported by Reuters. India’s MedGenome refiled its draft prospectus in late December 2025, per The Economic Times. Oxford Nanopore advanced a US ADR program in mid-December, per the Financial Times and SEC filings. These developments collectively point to a cautious reopening for genetics listings across the US, Asia, and Europe.

How much capital are these genetics listings expected to raise?

Estimates vary by issuer and venue. Sources indicate Ultima Genomics could target roughly $300–500 million in US proceeds, per Bloomberg. GC Genome’s Kosdaq offering was reported in the KRW 140–170 billion range, according to Reuters. MedGenome’s refiled DRHP points to an INR 1,200–1,500 crore raise for Indian exchanges, The Economic Times noted. Oxford Nanopore’s ADR step is preparatory and not a primary capital raise, though it may set the stage for future US financing options.

What will issuers likely use IPO proceeds for in 2026?

Proceeds are expected to support manufacturing scale-up, product development, and commercial expansion. Ultima Genomics has emphasized scaling sequencing platform economics and manufacturing capacity, per Bloomberg’s report on its confidential filing. GC Genome highlighted expanding oncology and rare disease testing alongside R&D, according to Reuters’ summary of its listing plans. MedGenome intends to invest in laboratory expansion and broaden its test menu across Indian metros, The Economic Times reported. These priorities reflect investor focus on revenue visibility and gross margin expansion.

How are cross-border strategies influencing genetics IPOs?

Cross-border strategies widen investor access and liquidity. Oxford Nanopore’s US ADR program, reported by the Financial Times and documented with the SEC, is designed to broaden its US shareholder base while maintaining a London listing. This approach can reduce listing friction for US investors and potentially enable follow-on offerings. For Asia-based issuers like GC Genome, a domestic listing can be complemented by future GDR or ADR options, aligning with capital needs and regional investor specialization highlighted in Reuters’ deals coverage.

What is the outlook for genetics IPOs through mid-2026?

Dealmakers expect a selective but improving window, with platform technologies and clinically validated diagnostics leading. Renaissance Capital’s early January commentary points to a building US pipeline, though valuation discipline remains key. Bloomberg’s deals reporting suggests additional confidential submissions in Q1 2026 as rates stabilize and healthcare indices firm. Issuers with clear reimbursement pathways, regulatory visibility, and scalable platforms are likely to price successfully, while preclinical stories may face longer timelines or favor private financing extensions.

Ultima Genomics Files US IPO as GC Genome Debuts on Kosdaq

Sequencing upstart Ultima Genomics confidentially submits for a US IPO while South Korea’s GC Genome prices and lists on Kosdaq, signaling a cautious reopening of public markets for genetics. India’s MedGenome refiles its IPO papers and Oxford Nanopore advances a US ADR setup.

Published: January 14, 2026 By Dr. Emily Watson Category: Genetics

Ultima Genomics Files US IPO as GC Genome Debuts on Kosdaq

Executive Summary

Ultima Genomics confidentially submits for a US IPO, targeting an estimated $300–500 million raise, according to Bloomberg on January 9, 2026.
South Korea’s GC Genome prices its Kosdaq IPO and lists with a double-digit first-day gain on January 8, 2026, Reuters reported.
India’s MedGenome refiles its draft IPO prospectus in late December 2025 to raise roughly INR 1,200–1,500 crore for expansion, per The Economic Times.
Oxford Nanopore advances a US ADR program in mid-December as it considers broader capital access in 2026, per Financial Times coverage and SEC filings.

The Genetics IPO Window Reopens Cautiously

Genetics and genomic tools issuers are re-testing public markets as 2026 begins. On January 9, 2026, Ultima Genomics confidentially submitted a draft registration for a US IPO, with people familiar estimating proceeds in the $300–500 million range, Bloomberg reported. The submission arrives as IPO execution in healthcare shows signs of recovery following a slow 2025, a trend tracked by Renaissance Capital in its recent new-issue pipeline updates.

In South Korea, GC Genome priced its Kosdaq IPO and began trading on January 8, 2026, with shares opening higher and closing with double-digit gains, according to Reuters. The listing underscores appetite for diagnostics and genomic testing names regionally, even as US investors remain selective toward pre-revenue platforms. “We are entering the market with a focus on disciplined growth and clear clinical value,” the company said in its offering announcement, as cited by Reuters.

“Scaling the economics of sequencing to expand access is central to our mission,” said Gilad Almogy, CEO of Ultima Genomics, in a company statement aligned with the confidential filing timeline on January 9–10, 2026, Bloomberg reported...

Read the full article at BUSINESS 2.0 NEWS